LearnGlossaryMarketStocksSuperinvestorsSign in

CRBU

Caribou Biosciences, Inc.

Healthcare · $124M market cap

Verdict

We can't put a fair value on CRBU right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-40.0% a year✗
Sales growth11.5% a year✓
Free cash flow growth—?
Return on invested capital-59.0%✗

Follow CRBU

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds CRBU. Who we track

Lee Ainslie

Maverick Capital · as of Q2 2026

$1.1M

652,542 shares

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works